FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

The share of US adults taking GLP-1 medications to lose weight has reached a record 11%, a new Medicare program that began July 1 could drive that figure higher still.

In the phase 3 KEYNOTE-B15/EV-304 trial, perioperative pembrolizumab plus enfortumab vedotin reduced the risk of recurrence, progression, or death by 47% and improved overall survival by 35% over ...

Treatments for fibrodysplasia ossificans progressiva, gastroenteropancreatic neuroendocrine tumors, HIV, influenza, and multiple myeloma are under review.

For men with lower urinary tract symptoms (LUTS) attributable to benign prostatic hyperplasia (BPH) who are continuous users of tamsulosin, about one-third have ...

More than one-third of the young adults surveyed (36%) reported that they seek out an urgent care clinic for nonemergency health issues, while 68% of older adults said they contact their primary care ...

Label expansion establishes the therapy as the first VWF concentrate indicated for routine prophylaxis across all age groups ...

The expanded indication makes risankizumab the first IL-23 inhibitor available for pediatric patients weighing under 40kg with plaque psoriasis or psoriatic arthritis, supported by phase 3 OptIMMize ...

FDA Drug Approvals and Regulatory Updates Drug Pharmacologic class Indication More information Cardiovascular Disease Tryngolza (olezarsen) Apolipoprotein ...